CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Frida›
Analysis
Frida

Frida

Frida operates an online clinic providing ADHD diagnosis, treatment, and ongoing clinical care for Canadian adults.

Operating headquarters
Calgary, Alberta, CA🇨🇦
Founded
2022
Loading
Overview
Analysis
Compare
Employees
News
Library

Contents

  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths
  4. 04Pricing Strategy
  1. 01Products & Services
  2. 02Market Outlook
  3. 03Competitive Strengths
  4. 04Pricing Strategy

Product Overview

Frida provides virtual ADHD care for Canadian adults, combining a structured diagnostic assessment with continuing treatment. The clinic's CAD 599 assessment covers a 60-minute clinician consultation, anxiety and depression screening, and a personalized treatment plan, with follow-up appointments at CAD 99 for medication titration and prescription renewals.

Patients begin with a two-minute online self-assessment before booking a diagnostic call, and complete pre-appointment questionnaires reviewed by their clinician. Treatment follows the Canadian ADHD Practice Guidelines, and ongoing care includes between-appointment messaging plus check-ins every three months once a dose stabilizes.

Source: talkwithfrida.com

Market Outlook

Half of Canadian adults with ADHD remain undiagnosed, leaving a large untreated population for accessible assessment and treatment services. Public-system waits and the cost of in-person assessments keep demand flowing toward faster virtual options.

Canadian insurers report ADHD care among their fastest-growing claim categories, expanding coverage-backed access. As an independent company, Frida can invest directly in broadening its ADHD care across Canadian provinces.

Source: linkedin.com

Competitive Advantages

Frida prices its diagnostic assessment at CAD 599 with appointments in days, against in-person assessments its materials place near CAD 2,500 and public-system waits near six months. Diagnosis and treatment run entirely by phone, removing travel for patients outside major urban centres.

Flat transparent fees and reduced medication costs through an affiliated Calgary pharmacy keep continuing care affordable, with financial assistance available for lower-income patients. Between-appointment messaging and scheduled check-ins sustain the care relationship between visits.

Source: talkwithfrida.com

Pricing Strategy

Frida charges a one-time CAD 599 diagnostic assessment and CAD 99 per follow-up appointment, separating diagnosis costs from continuing care. A free two-minute self-assessment precedes booking, so the paid engagement starts at diagnosis.

The clinic lowers ongoing medication costs through its affiliated Calgary pharmacy and manufacturer co-pay assistance, and most patients pay under CAD 20 monthly for medication with many paying nothing. Financial assistance covers households with combined income at or below CAD 50,000, and insurer-provided health spending accounts can cover fees.

Source: talkwithfrida.com